MyFinsight
Home
Blog
About
Contact
Stock-based compensation
expense
$257,400K
(0.66%↑ Y/Y)
Depreciation and
amortization
$123,200K
(-2.92%↓ Y/Y)
Increase (decrease) in
accounts payable,...
$107,700K
(150.30%↑ Y/Y)
Increase in deferred
revenue
$99,600K
(462.71%↑ Y/Y)
Other, net
-$55,600K
(-1637.50%↓ Y/Y)
Decrease (increase) in
inventories
-$26,600K
(-117.47%↓ Y/Y)
Decrease in accounts
receivable
-$1,200K
(99.82%↑ Y/Y)
Net income
$727,200K
(-10.08%↓ Y/Y)
Total adjustments
$351,700K
(48.77%↑ Y/Y)
Canceled cashflow
$319,600K
Net cash provided by
operating activities
$1,078,900K
(3.23%↑ Y/Y)
Increase in prepaid
expenses and other assets
$198,600K
(10.64%↑ Y/Y)
Deferred income taxes
$96,000K
(-30.98%↓ Y/Y)
Gains on marketable
and other...
$25,000K
(-82.13%↓ Y/Y)
Net (decrease)
increase in cash, cash...
-$153,100K
(-125.35%↓ Y/Y)
Canceled cashflow
$1,078,900K
Proceeds from issuance of
common stock
$163,100K
(169.14%↑ Y/Y)
Sales or maturities of
marketable and other...
$2,606,500K
(-24.63%↓ Y/Y)
Net cash used in
financing activities
-$802,200K
(26.35%↑ Y/Y)
Canceled cashflow
$163,100K
Net cash (used in)
provided by investing...
-$428,900K
(-166.24%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$900K
(-250.00%↓ Y/Y)
Canceled cashflow
$2,606,500K
Repurchases of common stock
$794,300K
(-23.73%↓ Y/Y)
Dividends paid
$97,800K
(4.26%↑ Y/Y)
Payments in connection
with common stock...
$73,200K
(1602.33%↑ Y/Y)
Purchases of marketable
and other...
$2,755,900K
(8.53%↑ Y/Y)
Capital expenditures
$230,600K
(0.57%↑ Y/Y)
Payments for intangible
assets
$48,900K
(15.88%↑ Y/Y)
Back
Back
Cash Flow
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
source: myfinsight.com